More info…
Forest Laboratories, Inc. and Gedeon Richter Plc. announced preliminary top-line results from an 8-week phase II clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of bipolar depression.
September 4, 2010 By Leave a Comment
Forest Labs, Gedeon Richter announce phase II study results of cariprazine for bipolar depression
Speak Your Mind
You must be logged in to post a comment.